KR830002502A - Diagnosis test method of malignant tumor - Google Patents

Diagnosis test method of malignant tumor Download PDF

Info

Publication number
KR830002502A
KR830002502A KR1019800001518A KR800001518A KR830002502A KR 830002502 A KR830002502 A KR 830002502A KR 1019800001518 A KR1019800001518 A KR 1019800001518A KR 800001518 A KR800001518 A KR 800001518A KR 830002502 A KR830002502 A KR 830002502A
Authority
KR
South Korea
Prior art keywords
cancer
inhibitory protein
bleomycin
determination
concentration
Prior art date
Application number
KR1019800001518A
Other languages
Korean (ko)
Inventor
티. 크루크 스탠리
갈반 루이스
Original Assignee
알푸스 오. 죤슨
배일러칼리지 어넌 메디슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알푸스 오. 죤슨, 배일러칼리지 어넌 메디슨 filed Critical 알푸스 오. 죤슨
Publication of KR830002502A publication Critical patent/KR830002502A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Abstract

내용 없음No content

Description

악성 종양의 진단 검사방법Diagnosis test method of malignant tumor

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this content is publicly disclosed, the full text is not included.

Claims (3)

하기의 단계로 구성된 사람의 암을 추적하는 방법.A method of tracking a person's cancer consisting of the following steps. (ㄱ) 암을 분리하기 위해 환자의 혈청 채취 :(A) Collecting the patient's serum to isolate cancer: (ㄴ) 상기 샘플에서 저해 단백질 X의 농도 결정 :(B) Determination of the concentration of inhibitory protein X in the sample: (ㄷ) 암이 없는 환자 혈청으로 구성된 정상 저해단백질 농도와 (ㄴ)값과 비교, 정상치에 비해 저해단백질 X의 뚜렷한 감소는 암의 확률을 나타냄.(C) Compared to the normal inhibitory protein concentration and (b) values, which consist of serum from patients without cancer, a marked decrease in inhibitory protein X compared to normal values indicates the probability of cancer. 하기의 단계로 구성된 사람의 암을 추적하는 방법.A method of tracking a person's cancer consisting of the following steps. (ㄱ) 암을 분리하기 위해 환자의 혈청 채취 :(A) Collecting the patient's serum to isolate cancer: (ㄴ) PM-2DNA의 블레오마이신-유도분해 50%를 저해하는데 필요한 저해 단백질 X의 농도결정 :(B) Determination of the concentration of inhibitory protein X required to inhibit bleomycin-induced degradation 50% of PM-2DNA: (ㄷ) 암이 없는 환자 혈청으로 구성된 정상 IC50값과 단계(ㄴ)에서 추적된 값과 비교, 정상치에 비해 현저한 IC50값의 증가는 암의 확률을 나타냄.(C) Compared with the normal IC 50 value composed of patient serum without cancer and the value tracked in step (b), a significant increase in IC 50 value compared to the normal value indicates the probability of cancer. 단계 (L)의 IC50값이 다음 담계로 이루어진 청구범위 2에 따른 방법.The method according to claim 2, wherein the IC 50 value in step (L) consists of the following steps. (1) pH 9.5완충액에서 블레오마이신, PM-2DNA과 2-머캡토에탄올 용액을 지닌 혈액샘플 혼합물을 준비함.(1) Prepare a blood sample mixture with bleomycin, PM-2DNA and 2-mercaptoethanol solution in pH 9.5 buffer. (2) 온도 37℃로 30분간 단계(1)의 혼합물을 배양함.(2) Incubate the mixture of step (1) for 30 minutes at a temperature of 37°C. (3) pH12.1변성 완충액의 에티디움 브로마이드 혼합물에 단계(2)의 혼합물 정재수(ajiquot)를 첨가함.(3) To the mixture of ethidium bromide in pH12.1 denatured buffer, the mixture of step (2) was added with ajiquot. (4) 530nm여기상태와 590nm방출의 분광형광광도계로 단계(3)의 에티디움 브로마이드 : PM-2 DNA 혼합물의 형광성을 결정함.(4) Determination of the fluorescence of the ethidium bromide: PM-2 DNA mixture in step (3) with a 530 nm excitation state and a 590 nm emission spectrophotometer. (5) 블레오마이신을 함유안한 콘트를 샘플의 형광성 변이로부터 블레오마이신-유도 PM-2 DNA분해물의 저해 퍼센트를 결정함 :(5) Determination of percent inhibition of bleomycin-induced PM-2 DNA lysates from the fluorescent variation of the sample with bleomycin-free controls: (6) 로리법으로 저해 단백질 X의 농도를 결정함 :(6) Determination of the concentration of inhibitory protein X by the Lori method: (7) 단계(5)와 (6)에서 얻는 값으로 블레오마이신-유도 PM-2 DNA 분해물 50%를 저해하는데 필요한 저해 단백질 X의 농도를 결정함.(7) Determine the concentration of inhibitory protein X required to inhibit 50% of bleomycin-induced PM-2 DNA lysate with the values obtained in steps (5) and (6). ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: Disclosure is based on the original application.
KR1019800001518A 1979-04-10 1980-04-10 Diagnosis test method of malignant tumor KR830002502A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2873279A 1979-04-10 1979-04-10
US28732 1979-04-10

Publications (1)

Publication Number Publication Date
KR830002502A true KR830002502A (en) 1983-05-30

Family

ID=21845111

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019800001518A KR830002502A (en) 1979-04-10 1980-04-10 Diagnosis test method of malignant tumor

Country Status (24)

Country Link
JP (1) JPS55143441A (en)
KR (1) KR830002502A (en)
AR (1) AR222700A1 (en)
AT (1) AT365343B (en)
AU (1) AU536522B2 (en)
BE (1) BE882669A (en)
CH (1) CH644453A5 (en)
DE (1) DE3013837A1 (en)
DK (1) DK149980A (en)
ES (1) ES8103380A1 (en)
FI (1) FI801078A (en)
FR (1) FR2454099A1 (en)
GB (1) GB2047712B (en)
GR (1) GR67692B (en)
HU (1) HU183122B (en)
IE (1) IE49981B1 (en)
IL (1) IL59772A (en)
IT (1) IT1143135B (en)
LU (1) LU82345A1 (en)
NL (1) NL8002094A (en)
NO (1) NO801018L (en)
PH (1) PH15637A (en)
SE (1) SE8002602L (en)
ZA (1) ZA802141B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524644A1 (en) * 1985-07-10 1987-01-15 Heyl Chem Pharm UNDULIN AND ITS PEPTIDE FRAGMENTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE

Also Published As

Publication number Publication date
GB2047712B (en) 1983-02-23
LU82345A1 (en) 1980-12-16
AU5719380A (en) 1980-10-16
IT8048370A0 (en) 1980-04-09
DK149980A (en) 1980-10-11
BE882669A (en) 1980-10-06
HU183122B (en) 1984-04-28
FR2454099A1 (en) 1980-11-07
NO801018L (en) 1980-10-13
ES490396A0 (en) 1981-02-16
ZA802141B (en) 1981-04-29
CH644453A5 (en) 1984-07-31
AT365343B (en) 1982-01-11
ES8103380A1 (en) 1981-02-16
IE800693L (en) 1980-10-10
IL59772A (en) 1983-05-15
AR222700A1 (en) 1981-06-15
SE8002602L (en) 1980-12-09
FR2454099B1 (en) 1984-01-27
DE3013837A1 (en) 1980-10-30
NL8002094A (en) 1980-10-14
FI801078A (en) 1980-10-11
IE49981B1 (en) 1986-01-22
IT1143135B (en) 1986-10-22
JPS55143441A (en) 1980-11-08
ATA195780A (en) 1981-05-15
AU536522B2 (en) 1984-05-10
IL59772A0 (en) 1980-06-30
GB2047712A (en) 1980-12-03
GR67692B (en) 1981-09-07
PH15637A (en) 1983-03-11

Similar Documents

Publication Publication Date Title
牧村進 et al. Quantitative determination of bovine serum Haptoglobin and its elevation in some inflammatory diseases.
Biewenga et al. Lactate dehydrogenase isoenzyme (s) linked to IgA immunoglobulin in a patient with a myocardial infarction
Olsson et al. Gamma globulins of CSF and serum in multiple sclerosis: isoelectric focusing on polyacrylamide gel and agar gel electrophoresis
SE9103332D0 (en) METHOD FOR THE DIAGNOSIS OF BLOOD COAGULATION DESORDERS
Ogawa et al. Dynein 2. A new adenosine triphosphatase from sea urchin sperm flagella.
Searcy et al. A study of the specificity of the Berthelot colour reaction
ES516987A0 (en) A PROCEDURE FOR THE QUANTITATIVE DETERMINATION OF BLOOD COAGULATION FACTOR XII IN THE HUMAN BLOOD PLASMA.
EA200100264A1 (en) ANGIOCIDIN: AN ADHESIVE CELL TUMOR RECEPTOR SPECIFIC FOR CYS-SER-VAL-THR-CYS-GLY
Dunlap et al. Interconversion of the multiple forms of dihydrofolate reductase from amethopterin-resistant Lactobacillus casei
ATE38521T1 (en) NOVEL PROTEIN (PP13), METHODS FOR ITS ENCOURAGEMENT AND RECOVERY, AND ITS USE.
Titus et al. Plasma aminopeptidase activity (oxytocinase) in pregnancy and labor
KR830002502A (en) Diagnosis test method of malignant tumor
Haldar et al. Serological profiles in Indian post kala-azar dermal leishmaniasis
Omoto et al. The distribution of the group-specific component (Gc) subtypes in Japanese
Brackexridge The tyrosine and tryptophan content of blood serum in malignant disease
McCombs et al. A new ceruloplasmin variant, Cp Galveston
Yatzidis et al. An improved method for the simple and accurate colorimetric determination of urea with Ehrlich's reagent
Queen et al. Haptoglobin type determination using non-carcinogenic reagents results on 192 normal subjects in maryland
Kishi et al. Isoelectric analysis of B gene-associated α-galactosyltransferases in human serum and saliva
NO962596L (en) New tumor suppressor gene
Engle Jr et al. Separation of human hemoglobins by starch-gel zone electrophoresis
ATE109509T1 (en) ANTICOAGULATORY PROTEIN PP4-X, ITS PRODUCTION AND USE.
Titkov et al. HLA antigens in borderline and essential hypertension
EA199800087A1 (en) INTERMEDIATE COMPOUND FOR OBTAINING ARTHROPOCID OXADIAZINE
Gibbs Effect of blood on the assay of 6-phosphogluconate dehydrogenase in vaginal fluid